Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

Reversal of Hepatitis B Virus-Induced Systemic Immune Tolerance by Intrinsic Innate Immune Stimulation

Cytokines and Chemokines in HBV Infection

Reversal of Hepatitis B Virus-Induced Immune Tolerance by an Immunostimulatory 3P-Hbx-sirnas in a Retinoic Acid Inducible Gene I-dependent Manner

IL-12–Based Vaccination Therapy Reverses Liver-Induced Systemic Tolerance in a Mouse Model of Hepatitis B Virus Carrier

Prevention of Hepatitis B Infection through Breaking Antigen - specific T Cell Tolerance

Clearing Persistent Extracellular Antigen of Hepatitis B Virus: an Immunomodulatory Strategy to Reverse Tolerance for an Effective Therapeutic Vaccination

Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies

Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice.

The Role of Innate Immunity in HBV Infection

Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection

Interferon-γ Facilitates Hepatic Antiviral T Cell Retention for the Maintenance of Liver-Induced Systemic Tolerance

Research Advances in Immune Tolerance in Chronic Hepatitis B Virus Infection

Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity

Toward Curative Immunomodulation Strategies for Chronic Hepatitis B Virus Infection

Restoration of a Functional Antiviral Immune Response to Chronic HBV Infection by Reducing Viral Antigen Load: if Not Sufficient, is It Necessary?

Role and mechanism of action of intrahepatic intrinsic antigen-presenting cells in regulating anti-hepatitis B virus immune response

Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice

Focus on Dysregulated Adaptive Immunity in Chronic Hepatitis B: A Promising Direction for Immunotherapy

Intrahepatic Exhausted Antiviral Immunity in an Immunocompetent Mouse Model of Chronic Hepatitis B

HBV immune tolerance of HBs-transgenic mice observed through parabiosis with WT mice

Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B